Mimicking megakaryopoiesis in vitro using biomaterials: Recent advances and future opportunities
Source abstract
Abstract
Presently donor-derived platelets used in the clinic are associated with concerns about adequate availability, expense, risk of bacterial contamination and complications due to immunological reaction. To prevail over our dependence on transfusion of donor-derived platelets, efforts are being made to generate them in vitro. Development of biomaterials that support or mimic bone marrow niche micro-environmental cues could improve the in vitro production of platelets from megakaryocytes (MKs) derived from various stem cell sources. In spite of significant advances in the production of MKs from various stem cell sources using 2D as well as 3D culture approaches in vitro and the development of biomaterials-based platelet systems, yield and quality of these platelets remains unsuitable for clinical use. Thus, in vitro production of clinically useful platelets on a large scale remains an unmet target to date. This review summarizes the most frequently used 2D and 3D approaches to generate MKs and platelets in vitro, emphasizing the importance of mimicking in vivo micro-environment. Further, this review proposes the use of interpenetrating network (IPN) biomaterial-based approach as a promising strategy for improving the generation of MK and platelets in sufficient numbers in vitro. STATEMENT OF SIGNIFICANCE: Thrombocytopenia is one of the major global health and socio-economic problems. Transfusion with donor-derived platelets (PLTs) is the only effective treatment for this condition. However, this approach is limited by factors like short shelf-life of PLTs, PLT activation, alloimmunization, risk of bacterial contamination, infection etc. In vitro generated MKs and PLTs derived from non-donor-dependent sources may help to overcome the platelet transfusion concerns. Here we have reviewed various 2D and 3D strategies used for in vitro generation of MKs and PLTs, with special emphasis on various biomaterial platforms and different physico/chemical cues being used for the purpose. We have also proposed a biomaterial-based approach of using interpenetrating network (IPN) for generating clinically relevant numbers of MKs and PLTs.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Platelet Disorders and Treatments · Periodontal Regeneration and Treatments · Blood properties and coagulation
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (93)
Show source-provided references
1. Recent developments in ex vivo platelet production10.1007/s10616-016-9963-4 ↗
2. In vitro generation of platelets: where do we stand?10.1016/j.tracli.2017.06.013 ↗
3. Towards the manufacture of megakaryocytes and platelets for clinical application10.1159/000477261 ↗
4. On the way to in vitro platelet production10.3389/fmed.2018.00239 ↗
5. The lung is a site of platelet biogenesis and a reservoir for haematopoietic progenitors10.1038/nature21706 ↗
6. Structurally graduated collagen scaffolds applied to the ex vivo generation of platelets from human pluripotent stem cell-derived megakaryocytes: Enhancing production and purity10.1016/j.biomaterials.2018.08.019 ↗
7. In vitro megakaryocyte production and platelet biogenesis: state of the art10.1016/j.tmrv.2009.09.003 ↗
8. Road blocks in making platelets for transfusion10.1111/jth.12942 ↗
9. Understanding platelet generation from megakaryocytes: implications for in vitro-derived platelets10.1182/blood-2015-08-607929 ↗
10. Progress in bio-manufacture of platelets for transfusion10.1080/09537104.2016.1257783 ↗
11. Platelet bioreactor: accelerated evolution of design and manufacture10.1080/09537104.2016.1265922 ↗
12. Threading an elephant through the eye of a needle: Where are platelets made?10.1038/cr.2017.65 ↗
13. A novel role of sphingosine 1-phosphate receptor S1pr1 in mouse thrombopoiesis10.1084/jem.20121090 ↗
14. IL-1alpha induces thrombopoiesis through megakaryocyte rupture in response to acute platelet needs10.1083/jcb.201410052 ↗
15. Ex vivo production of platelets from stem cells10.1111/bjh.12764 ↗
16. Manipulating megakaryocytes to manufacture platelets ex vivo10.1111/jth.12946 ↗
17. Enabling large-scale ex vivo production of megakaryocytes from CD34(+) cells using gas-permeable surfaces10.1002/sctm.18-0160 ↗
18. Constructing 3D microenvironments using engineered biomaterials for HSC expansion10.1089/ten.teb.2018.0286 ↗
19. Direct hydrogel encapsulation of pluripotent stem cells enables ontomimetic differentiation and growth of engineered human heart tissues10.1016/j.biomaterials.2015.12.011 ↗
20. On human pluripotent stem cell control: The rise of 3D bioengineering and mechanobiology10.1016/j.biomaterials.2015.01.078 ↗
21. Human pluripotent stem cell mechanobiology: Manipulating the biophysical microenvironment for regenerative medicine and tissue engineering applications10.1002/stem.2105 ↗
22. Platelets generated from human embryonic stem cells are functional in vitro and in the microcirculation of living mice10.1038/cr.2011.8 ↗
23. Megakaryocytes derived from human embryonic stem cells: a genetically tractable system to study megakaryocytopoiesis and integrin function10.1111/j.1538-7836.2006.01744.x ↗
24. Generation of functional platelets from human embryonic stem cells in vitro via ES-sacs, VEGF-promoted structures that concentrate hematopoietic progenitors10.1182/blood-2007-10-117622 ↗
25. Induced pluripotent stem cell-derived megakaryocytes and platelets for disease modeling and future clinical applications10.1161/ATVBAHA.117.309197 ↗
26. Scalable generation of universal platelets from human induced pluripotent stem cells10.1016/j.stemcr.2014.09.010 ↗
27. Large-scale production of megakaryocytes from human pluripotent stem cells by chemically defined forward programming10.1038/ncomms11208 ↗
28. vitro platelets in sight10.1182/blood-2014-08-592493 ↗
29. Large-scale production of megakaryocytes in microcarrier-supported stirred suspension bioreactors10.1038/s41598-018-28459-x ↗
30. Microfluidic model of the platelet-generating organ: beyond bone marrow biomimetics10.1038/srep21700 ↗
31. Multiple membrane extrusion sites drive megakaryocyte migration into bone marrow blood vessels
32. Platelet bioreactor-on-a-chip10.1182/blood-2014-05-574913 ↗
33. Programmable 3D silk bone marrow niche for platelet generation ex vivo and modeling of megakaryopoiesis pathologies10.1182/blood-2014-08-595561 ↗
34. Microvasculature-directed thrombopoiesis in a 3D in vitro marrow microenvironment10.1371/journal.pone.0195082 ↗
35. The biogenesis of platelets from megakaryocyte proplatelets10.1172/JCI26891 ↗
36. Dynamic visualization of thrombopoiesis within bone marrow10.1126/science.1146304 ↗
37. Human mesenchymal stem cells support megakaryocyte and pro-platelet formation from CD34(+) hematopoietic progenitor cells10.1002/(SICI)1097-4652(200007)184:1<58::AID-JCP6>3.0.CO;2-B ↗
38. The secret life of a megakaryocyte: emerging roles in bone marrow homeostasis control10.1007/s00018-014-1813-y ↗
39. Haematopoietic stem cell activity and interactions with the niche10.1038/s41580-019-0103-9 ↗
40. Effects of vascular endothelial growth factors and their receptors on megakaryocytes and platelets and related diseases10.1111/bjh.15000 ↗
41. Autocrine-paracrine VEGF loops potentiate the maturation of megakaryocytic precursors through Flt1 receptor10.1182/blood-2002-07-2184 ↗
42. Megakaryocytes, malignancy and bone marrow vascular niches10.1111/j.1538-7836.2011.04571.x ↗
43. Mpl expression on megakaryocytes and platelets is dispensable for thrombopoiesis but essential to prevent myeloproliferation10.1073/pnas.1404354111 ↗
44. TPO-independent megakaryocytopoiesis10.1016/j.critrevonc.2007.11.003 ↗
45. Stromal-derived factor 1 and thrombopoietin regulate distinct aspects of human megakaryopoiesis10.1182/blood.V96.13.4142 ↗
46. The Mpl-ligand or thrombopoietin or megakaryocyte growth and differentiative factor has both direct proliferative and differentiative activities on human megakaryocyte progenitors10.1182/blood.V86.7.2516.2516 ↗
47. Interleukin-6 stimulates thrombopoiesis through thrombopoietin: role in inflammatory thrombocytosis10.1182/blood.V98.9.2720 ↗
48. Recombinant human interleukin-11 directly promotes megakaryocytopoiesis in vitro10.1182/blood.V90.10.3893 ↗
49. SDF-1 dynamically mediates megakaryocyte niche occupancy and thrombopoiesis at steady state and following radiation injury10.1182/blood-2014-01-547638 ↗
50. Chemokine-mediated interaction of hematopoietic progenitors with the bone marrow vascular niche is required for thrombopoiesis10.1038/nm973 ↗
51. Shaping of terminal megakaryocyte differentiation and proplatelet development by sphingosine-1-phosphate receptor S1P4
52. Platelet factor 4 regulates megakaryopoiesis through low-density lipoprotein receptor-related protein 1 (LRP1) on megakaryocytes10.1182/blood-2009-04-216473 ↗
53. Adhesive receptors, extracellular proteins and myosin IIA orchestrate proplatelet formation by human megakaryocytes10.1111/j.1538-7836.2008.03132.x ↗
54. Regulation of proplatelet formation and platelet release by integrin alpha IIb beta310.1182/blood-2005-11-011957 ↗
55. Characterization and functionality of cell surface molecules on human mesenchymal stem cells10.1007/BF02256058 ↗
56. Cotransplantation of human mesenchymal stem cells enhances human myelopoiesis and megakaryocytopoiesis in NOD/SCID mice10.1016/S0301-472X(03)00042-0 ↗
57. Osteoblasts support megakaryopoiesis through production of interleukin-910.1182/blood-2016-11-749838 ↗
58. Microenvironmental regulation of hematopoietic stem cells and its implications in leukemogenesis10.1097/MOH.0000000000000251 ↗
59. Bone marrow osteoblastic niche: a new model to study physiological regulation of megakaryopoiesis10.1371/journal.pone.0008359 ↗
60. Impairment of hematopoietic stem cell niches in patients with aplastic anemia10.1007/s12185-015-1881-2 ↗
61. Paracrine regulation of megakaryo/thrombopoiesis by macrophages10.1016/j.exphem.2011.03.009 ↗
62. Importance of environmental stiffness for megakaryocyte differentiation and proplatelet formation10.1182/blood-2016-02-699959 ↗
63. Shear enhances thrombopoiesis and formation of microparticles that induce megakaryocytic differentiation of stem cells10.1182/blood-2014-01-547927 ↗
64. Turbulence activates platelet biogenesis to enable clinical scale ex vivo production
65. Understanding hematopoietic stem-cell microenvironments10.1016/j.tibs.2006.08.001 ↗
66. Oxygen tension influences the differentiation, maturation and apoptosis of human megakaryocytes10.1111/j.1365-2141.2000.02457.x ↗
67. Prolonged continuous in vitro human platelet production using three-dimensional scaffolds10.1016/j.exphem.2008.09.009 ↗
68. Manipulation of oxygenation and flow-induced shear stress can increase the in vitro yield of platelets from cord blood10.1089/ten.tec.2011.0108 ↗
69. Three-dimensional system for the in vitro study of megakaryocytes and functional platelet production using silk-based vascular tubes10.1089/ten.tec.2011.0134 ↗
70. Two differential flows in a bioreactor promoted platelet generation from human pluripotent stem cell-derived megakaryocytes10.1016/j.exphem.2013.04.007 ↗
71. Three-dimensional environment sustains hematopoietic stem cell differentiation into platelet-producing megakaryocytes10.1371/journal.pone.0136652 ↗
72. A novel bioreactor and culture method drives high yields of platelets from stem cells10.1111/trf.13375 ↗
73. Culturing and differentiation of murine embryonic stem cells in a three-dimensional fibrous matrix10.1023/A:1024283521966 ↗
74. Exposure of human megakaryocytes to high shear rates accelerates platelet production10.1182/blood-2009-03-209205 ↗
75. Cytoskeletal mechanics of proplatelet maturation and platelet release10.1083/jcb.201006102 ↗
76. Separation of in-vitro-derived megakaryocytes and platelets using spinning-membrane filtration10.1002/bit.25477 ↗
77. Using computational fluid dynamics (CFD) to enhance ex vivo platelet production via shear forces within microfluidic bioreactors10.1182/blood.V128.22.1352.1352 ↗
78. A uniform-shear rate microfluidic bioreactor for real-time study of proplatelet formation and rapidly-released platelets10.1002/btpr.2563 ↗
79. A new path to platelet production through matrix sensing10.3324/haematol.2016.161562 ↗
80. Biological implications of polydimethylsiloxane-based microfluidic cell culture10.1039/b903043c ↗
81. PDMS absorption of small molecules and consequences in microfluidic applications10.1039/b612140c ↗
82. Integrated biophysical and biochemical signals augment megakaryopoiesis and thrombopoiesis in a three-dimensional rotary culture system10.5966/sctm.2015-0080 ↗
83. Hierarchically designed agarose and poly(ethylene glycol) interpenetrating network hydrogels for cartilage tissue engineering10.1089/ten.tec.2009.0761 ↗
84. Using chondroitin sulfate to improve the viability and biosynthesis of chondrocytes encapsulated in interpenetrating network (IPN) hydrogels of agarose and poly(ethylene glycol) diacrylate10.1007/s10856-011-4499-9 ↗
85. Incorporation of aggrecan in interpenetrating network hydrogels to improve cellular performance for cartilage tissue engineering10.1089/ten.tea.2012.0160 ↗
86. The bioactivity of agarose-PEGDA interpenetrating network hydrogels with covalently immobilized RGD peptides and physically entrapped aggrecan10.1016/j.biomaterials.2014.01.002 ↗
87. Collagens–structure, function, and biosynthesis10.1016/j.addr.2003.08.002 ↗
88. Collagens and collagen-related diseases10.3109/07853890109002055 ↗
89. 1994
90. Chondroitin sulfate-based biomaterials for tissue engineering10.3906/biy-1507-16 ↗
91. Hyaluronic acid/chondroitin sulfate-based hydrogel prepared by gamma irradiation technique10.1016/j.carbpol.2013.11.048 ↗
92. Hyaluronic acid-based clinical biomaterials derived for cell and molecule delivery in regenerative10.1016/j.jconrel.2011.04.007 ↗
93. Enhanced generation of megakaryocytes from umbilical cord blood-derived CD34(+) cells expanded in the presence of two nutraceuticals, docosahexanoic acid and arachidonic acid, as supplements to the cytokine-containing medium10.3109/14653241003588858 ↗